Kidney Cancer Awareness: Multidisciplinary Care is the Key

Pictured left to right: Dr. Padraic O’Malley, Dr. Paul Crispen, Dr. Wayne Brisbane, Dr. Brian Ramnaraign, Dr. Jonathan Chatzkel. Not pictured: Dr. Robert Zlotecki, Dr. Jeffrey Vogel

Kidney cancer is among the 10 most common cancers for men and women. In 2022, about 79,000 new cases of kidney cancer will be diagnosed. While many of these cases tend to be in those over the age of 45 and occur more often for men, kidney cancer can affect anyone.

Because kidney cancer can occur for anyone and in varying levels of severity, it is crucial that treatment for kidney cancer is personalized for the patient. At UF Health, urologists, medical oncologists and radiation oncologists work together to develop individualized, multidisciplinary treatment plans for each patient’s circumstances based on age, general health, life expectancy and tumor characteristics.

“It is incredibly important for locally advanced and metastatic cancer patients to have access to multi-modal therapies. The way we sequence these treatments, we can tailor treatment designs to individual patients to optimize their cancer care and maintain or improve their quality of life. It is a massive focus of what we do at UF Health Urology,” said Padriac O’Malley, MD, MSc, FRCSC, assistant professor in the department of urology at the University of Florida College of Medicine.

New Clinical Trials Open for Enrollment

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

A Phase 2, open-label, non-randomized study evaluating the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, & 5 of each cycle, in patients 61 years or older with acute myeloid leukemia (AML).

Principal Investigator: Jack Hsu, M.D. | Cell: 352-672-0704

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

A Phase 2, randomized study that investigates the use of the Signaterra ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer. The aim of this study will be to measure and compare the overall survival, progression-free survival, and best overall response while on study of patients whose treatment has been guided by these two approaches.

Principal Investigator: Sherise Rogers, M.D. | Cell: 718-614-5727 

A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual Disease

Patients with locally advanced TNBC are at high risk of developing lethal metastatic disease within 2 years of diagnosis, especially for those without a pathologic complete response (pCR) after neoadjuvant chemotherapy. This study will advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. 

Principal Investigator: Karen Daily, DO | Cell: 352-222-1423

Study of JTX 8064 in Combination with a PD-1 Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumors

A Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of JTX-8064.  JTX-8064 is a humanized mAB designed to block interaction of LILRB2 with its known ligands, and is administered IV in combination with a PD-1 inhibitor every 3 weeks. Cohorts are available for Squamous Cell Head and Neck cancer, platinum-resistant Ovarian cancer, Non-Small Cell Lung cancer, Cutaneous Squamous Cell Carcinoma, Undifferentiated Pleomorphic Sarcoma, and Liposarcoma.  

Principal Investigator: Thomas George, M.D. | Cell: 352-339-6672